James A. Crowell
Neuroscience · Indiana University
Publications
272
Citations
17,602
Est. group size
—
Recurring co-author estimate
Active years
52
Publishing since 1974
James A. Crowell's research focuses on cancer prevention (chemoprevention) and the early molecular changes that occur in cells before cancer develops. Much of the work involves studying gene and protein activity in normal-appearing tissues from people at high genetic risk (such as carriers of BRCA1/BRCA2 mutations), as well as screening combinations of anticancer drugs to identify pairs with enhanced effects.
Publication activity has generally grown over the decade, with a notable spike in 2023, though counts are lower in the most recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Data from The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity
2023
- Supplementary Data 1-13 from One-Hit Effects in Cancer: Altered Proteome of Morphologically Normal Colon Crypts in Familial Adenomatous Polyposis
2023
- Supplementary Information from The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity
2023
- Supplementary Information from The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity
2023
- Supplementary Data 1-13 from One-Hit Effects in Cancer: Altered Proteome of Morphologically Normal Colon Crypts in Familial Adenomatous Polyposis
2023
- Supplementary Methods, Tables 1-3, Figure 1 from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> Mutations
2023
- Supplementary Methods, Tables 1-3, Figure 1 from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> Mutations
2023
- Data from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> Mutations
2023
- Perspective on this Article from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> Mutations
2023
- Perspective on this Article from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> Mutations
2023
- Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668
2023
- Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668
2023
- Data from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> Mutations
2023
- Data from The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity
2023
- Data from One-Hit Effects in Cancer: Altered Proteome of Morphologically Normal Colon Crypts in Familial Adenomatous Polyposis
2023
- Investigative Ophthalmology & Visual Science×5
- Proceedings of the National Academy of Sciences×2
- Human Factors The Journal of the Human Factors and Ergonomics Society×2
- Journal of Biomedical Optics×2
- Oncotarget×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile